| Title |
Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2– advanced breast cancer
|
|---|---|
| Published in |
Drug Design, Development and Therapy, February 2018
|
| DOI | 10.2147/dddt.s137783 |
| Pubmed ID | |
| Authors |
Silvia Paola Corona, Daniele Generali |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Italy | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 165 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 165 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 28 | 17% |
| Student > Ph. D. Student | 20 | 12% |
| Student > Master | 13 | 8% |
| Researcher | 9 | 5% |
| Other | 7 | 4% |
| Other | 18 | 11% |
| Unknown | 70 | 42% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 23 | 14% |
| Medicine and Dentistry | 21 | 13% |
| Pharmacology, Toxicology and Pharmaceutical Science | 14 | 8% |
| Agricultural and Biological Sciences | 10 | 6% |
| Chemistry | 5 | 3% |
| Other | 13 | 8% |
| Unknown | 79 | 48% |
Attention Score in Context
This research output has an Altmetric Attention Score of 10. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 November 2021.
All research outputs
#3,711,927
of 25,382,440 outputs
Outputs from Drug Design, Development and Therapy
#231
of 2,268 outputs
Outputs of similar age
#80,309
of 448,849 outputs
Outputs of similar age from Drug Design, Development and Therapy
#7
of 42 outputs
Altmetric has tracked 25,382,440 research outputs across all sources so far. Compared to these this one has done well and is in the 85th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,268 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.1. This one has done well, scoring higher than 89% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 448,849 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 81% of its contemporaries.
We're also able to compare this research output to 42 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 83% of its contemporaries.